ISPE announced seven keynote speakers for the 2022 ISPE Annual Meeting & Expo, taking place 30 October–2 November 2022 in Orlando, Florida, and virtually. This signature event brings together top pharmaceutical industry and regulatory leaders offering compelling presentations and interactive discussions on industry-critical technical developments.
The 2022 ISPE Annual Meeting & Expo features a dynamic line-up of thought-provoking keynote presentations led by some of the most prominent names in the pharmaceutical industry.
Andres Angelani is the Senior Vice President and Global Head of Digital Engineering at Cognizant, a leading provider of information technology, consulting and business process services. He is a proven leader at blending design and engineering disciplines that not only boost business performance, but also help organizations build modern business that can seize the potential of the digital revolution.
Tom Cheslock is currently the Vice President, Global Supply Chain of Pfizer’s Hospital Business Unit (HBU), and a member of the Global Supply Chain Leadership Team. He is the primary Pfizer Global Supply (PGS) interface to the Global HBU Commercial Business Unit with accountability for achieving customer service targets including escalation and coordination of supply resolution and optimized inventory targets.
Joydeep Ganguly is Senior Vice President, Corporate Operations at Gilead Sciences. In his current role, he is accountable for several strategic functions, including corporate engineering and operations; infrastructure and capital planning; sustainability; risk management and resilience; global procurement; and the program management office. Mr. Ganguly also oversees Gilead’s footprint strategy and corporate real estate portfolio.
Julie Kim is President of Takeda’s U.S. Business Unit and U.S. Country Head. Ms. Kim has nearly 30 years of experience in health care, 15 of those in international leadership positions. She joined Takeda in 2019 through the acquisition of Shire, where throughout her time she held many diverse roles with increasing responsibility through her time at Baxter/Baxalta/Shire. In 2020, Ms. Kim was instrumental in bringing together most of the plasma companies to form the CoVIg-19 Plasma Alliance, to develop and manufacture a potential therapy to treat COVID-19.
Michael Kopcha, PhD, RPh, is the Director of the FDA’s Office of Pharmaceutical Quality (OPQ). This office has over 1,300 staff responsible for assuring the availability of quality medicines for the American public through assessment, inspection, surveillance, research, and policy. Prior to joining the FDA, Dr. Kopcha amassed more than 25 years of experience in major and mid-sized innovator, generic, drug/device, and over-the counter (OTC) pharmaceutical and consumer health companies.
Peter Marks joined the FDA in 2012 as Deputy Center Director for CBER and became Center Director in 2016. Dr. Marks is board certified in internal medicine, hematology, and medical oncology, and is a Fellow of the American College of Physicians. Prior to the FDA, Dr. Marks worked for several years in the pharmaceutical industry on the clinical development of hematology and oncology products prior to returning to academic medicine at Yale University where he led the Adult Leukemia Service and served as Chief Clinical Officer of Smilow Cancer Hospital.
Thomas Wozniewski is Global Manufacturing & Supply Officer of Takeda Pharmaceutical Company Ltd. He was appointed to this role in July 2014. Mr. Wozniewski has focused on the globalization, the technological and digital transformation and the implementation of a continuous and agile improvement culture within the manufacturing network of more than30 manufacturing sites. Mr. Wozniewski has more than 20 years of experience in the pharmaceutical industry.